Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts

International Journal of Cancer

Volumn 123, Issue 1, 2008, Pages 202-208

  Littlejohn, James E ^a,b   Cao, Xiaobo ^b   Miller, Steven D ^c   Ozvaran, Mustafa K ^c   Jupiter, Daniel ^a   Zhang, Lidong ^b   Rodarte, Charles ^b   Smythe, W Roy ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antisense oligonucleotide; Bcl xL; Cisplatin; Combination therapy; Mesothelioma

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ASO 15999; CISPLATIN; INTERLEUKIN 12; PROTEIN BCL XL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CELL VIABILITY; CHEMOSENSITIZATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALE; METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; TUMOR XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-X PROTEIN; CELL LINE, TUMOR; CISPLATIN; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAPERITONEAL; KAPLAN-MEIERS ESTIMATE; MESOTHELIOMA; MICE; MICE, SCID; OLIGONUCLEOTIDES, ANTISENSE; PLEURAL NEOPLASMS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 43949111975     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23452     Document Type: Article

References (27)

1. Available at: http://apps.nccd.cdc.gov/USCS/Table.aspx7Group= TableAll&Year=2003.
2. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-93.
3. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996;14:1007-17.
4. Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993;103:373S-376S.
5. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995;107:332S-344S.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
7. Ozvaran MK, Cao XX, Miller SD, Monia BA, Hong WK, Smythe WR. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Therapeut 2004;3:545-50.
8. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003:22:7265-79.
9. Gleave ME, Monia BP. Antisense therapy for cancer. Nature reviews. 2005;5:468-79.
10. Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA, Zangemeister-Wittke U. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001;93:463-71.
11. Smythe WR, Mohuiddin I, Ozveran M, Cao XX. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 2002;123:1191-8.
12. Smythe WR, Hwang HC, Amin KM, Eck SL, Davidson BL, Wilson JM, Kaiser LR, Albelda SM. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994;54:2055-9.
13. Boenisch T SR, Farmilo AJ, Key M, Welcher R, Harvey R, Atwood KN. Immunochemical staining methods. Carpinteria, CA, Dako: 3rd edn., 2001.
14. Heidel JD, Hu SW, Liu XF, Triche TJ, Davis ME. Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 2004;22:1579-82.
15. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev 2002;2:277-88.
16. L sequesters its C-terminal membrane anchor in soluble, cytosolic homodimers. Eur Mol Biol Organ (EMBO) 2004;23:2146-55.
17. Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005;8:5-6.
18. Shangary S, Johnson DE. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 2003;17:1470-81.
19. De Mesmaeker A, Haner R, Martin P, Moser HE. Antisense Oligonucleotides. Acc Chem Res 1995;28:366-74.
20. Vogelzang NJ, Porta C, Mutti L. New agents in the management of advanced mesothelioma. Semin Oncol 2005;32:336-50.
21. Green JDY, Dodd S, Dickson R, Walley T. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database Syst Rev 2007;3:1-15.
22. Zhu H, Guo W, Zhang L, Davis JJ, Teraishi F, Wu S, Cao X, Daniel J, Smythe WR, Fang B. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Therapeut 2005;4:451-6.
23. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
24. DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW, Zhao Z, Huber HE, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Therapeut 2005;4:271-9.
25. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ, Coppola D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 2003;63:7708-16.
26. Vilenchik M, Raffo AJ, Benimetskaya L, Shames D, Stein CA. Antisense RNA down-regulation of bcl-xL expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res 2002;62:2175-83.
27. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun (BBRC) 2005;333:336-43.